Moderna Faces Tough Times with Price Target Reduced to $55
Moderna's Price Target Adjustment and Challenges
Recently, prominent analysts at Jefferies have downgraded their outlook on Moderna (NASDAQ: MRNA), reducing the price target to $55 from the previous $65. This adjustment is driven by several underlying factors, including lower-than-expected guidance for upcoming years and delays in the much-anticipated cost reductions. Their second-quarter earnings report raised concerns as forecasts for 2024 were notably reduced, coupled with subsequent announcements during the R&D day that left expectations for 2025 diminished.
Competitive Landscape and Financial Woes
One significant cause of concern is the anticipated performance of Moderna's Respiratory Syncytial Virus (RSV) vaccine. Current projections for 2024 are modest at best, and there remains a cloud of uncertainty surrounding the company's ability to procure contracts in 2025. Still, competitive pressures from pharmaceutical giants, namely GSK and Pfizer (NYSE: PFE), exacerbate this complexity, especially with the ambiguity surrounding vaccine recommendations for the forthcoming RSV season. Analysts have also flagged Moderna's high cash burn rate, which remains elevated at $5-6 billion. As a result, profitability forecasts have been pushed back to 2028, changing from earlier expectations set for 2026.
Looking Ahead: Potential for Growth
Despite these hurdles, some optimism lingers. Analysts suggest that positive interim results from the Cytomegalovirus (CMV) vaccine could provide a much-needed boost to the stock in the near future. When discussing the financial outlook for the third quarter, Moderna projects revenues between $2.6-3.2 billion for the remainder of the year. They expect approximately 40% of COVID-19 revenues to be recorded in the third quarter, with predictions of about $1-1.2 billion for that specific quarter.
Revenue Estimates and Projections
The latest forecasts estimate around $1 billion in revenue, with an anticipated $540 million coming from U.S. sales. These estimates rely on 4 million tracked retail prescriptions and an anticipated 30% share from non-retail channels at a net price of $80 per shot. The company's guidance for the second half shows a projected split of about $670 million each from the Advanced Purchase Agreement (APA) and ex-U.S. COVID-19 sales. This scenario implies roughly $270 million for each segment during the third quarter, culminating in approximately $540 million in total—substantially lower than the consensus estimate of around $1.2 billion.
Leadership Changes and Clinical Trials
In a move towards enhancing its strategic positioning, Moderna has recently appointed Abbas Hussain, the previous CEO of Vifor Pharma and Global President of GlaxoSmithKline's Pharmaceuticals and Vaccines, to its board of directors. His extensive industry experience is expected to be instrumental in guiding Moderna's commercialization efforts on a global scale.
New Vaccine Trials and Product Launches
Further advancing its portfolio, Moderna has initiated a pivotal Phase 3 clinical trial for its investigational norovirus vaccine, mRNA-1403, aiming to enroll roughly 25,000 participants across the globe. Additionally, the company has received approval from Health Canada for its updated COVID-19 vaccine, SPIKEVAX®, which is set to be deployed for the 2024-2025 season.
Market Outlook and Analyst Reactions
Recent adjustments by various analyst firms signify a cautious outlook for Moderna. For instance, Piper Sandler has lowered its target for the company from $157 to $115 while maintaining an Overweight rating. Meanwhile, Oppenheimer has relegated the company's stocks to a neutral status, indicating a Perform rating. Similarly, RBC Capital has adjusted its price target from $90 to $75, reflecting growing skepticism about Moderna's future profitability and revenue generation capabilities.
Overall, Moderna estimates its product sales to be between $3 billion and $3.5 billion for the current year, looking to navigate through challenging financial waters. However, the timeline for reaching cash flow breakeven has been deferred to 2028, which includes projected revenue around $6.0 billion—an essential consideration for investors monitoring the company's trajectory.
Frequently Asked Questions
What led Jefferies to cut Moderna's price target?
Jefferies cut Moderna's price target due to lower-than-expected guidance, competition, and delays in cost reductions.
How does Moderna plan to improve its revenue?
Moderna anticipates significant revenue from COVID-19 sales, and potential growth from its upcoming CMV vaccine data.
What are the financial challenges facing Moderna?
Moderna faces high cash burn rates and delayed profitability forecasts, now pushed to 2028.
Who has been appointed to Moderna's board recently?
Abbas Hussain, former CEO of Vifor Pharma, has been appointed to Moderna's board to enhance commercialization efforts.
What is the status of Moderna's RSV vaccine?
Projections for Moderna's RSV vaccine are currently minimal for 2024, raising concerns about future contracts.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Exploring the Bright Future of Arm Holdings: A Stock to Watch
- DexCom, Inc. Investors: Important Class Action Deadline Ahead
- Investor Concerns Raise Issues on Verizon's Frontier Deal
- Changing Fortunes: Why German Automakers Are Falling Behind
- FOX News Digital Surges Ahead with Record Viewership Growth
- Impact of Israeli Military Plans on Crude Oil Prices Explained
- Transforming Healthcare: The Clinician's Partnership with Queensland Health
- Tevogen Bio's Visionary Steps Towards Enhancing Shareholder Transparency
- Funding Boost for MEDiC Life Sciences to Advance Cancer Treatment
- Legal Investigations Encourage Participation for Long-Term Investors
Recent Articles
- Market Reactions to Recent Developments in Key Stocks
- Top Wealth Group Secures $10.8 Million Through Share Offering
- GEICO Sets Up Inspection Sites in Florida After Hurricane
- Exploring the Dynamics of Roku's Options Trading Landscape
- Onto Innovation's Upcoming Q3 2024 Financial Results Overview
- Understanding MARA Holdings' Growing Options Market Trends
- Stewart Information Services to Discuss Q3 2024 Results Soon
- Investor Insights: Unpacking the Swan Song for HLT Options
- United Airlines Prepares for Q3 with New Routes and Challenges
- Goldman Sachs Predicts Stock Boost with Trump Victory
- CBL Properties Declares Significant Dividend and Expansion Plans
- DCG ONE Enhances Marketing Services with Cirangle Design Buyout
- Sanjiv Razdan Takes the Helm as CEO of The Joint Corp.
- PTC Therapeutics Advances with New Drug Application for PKU Drug
- Phillips 66 Divests Key Stake as Part of Strategic Restructuring
- Modine Manufacturing's New CIO Sets Strategic Digital Vision
- Winnebago's Strategic Shift: Leadership in Towable RVs
- Coty Inc. Sees Steady Growth Despite Market Challenges Ahead
- Leadership Changes in AI: Microsoft VP Moves to OpenAI
- Brazilian Stock Market Gains Strong Momentum Amid Diverse Sectors
- U.S. Stock Markets Surge: Key Players and Sector Highlights
- Tesla's Humans Behind Optimus Bots at Recent Robotaxi Showcase
- Sabadell Chair Highlights Risks of Banking Consolidation Effects
- The Joint Corp. Welcomes Sanjiv Razdan as New CEO
- Empowering Cybersecurity Training Through Real-World Scenarios
- Legacy Housing's Upcoming Earnings Call and What to Expect
- Shoals Technologies Group Set to Share Q3 Earnings Insights Soon
- Summary of Company Shares and Voting Rights Information
- Exploring Travere Therapeutics' Latest Insights into Kidney Health
- Tragic Tesla Crash Claims Four Lives in Fiery Incident
- Voting Rights and Share Information of the Company
- Travere Therapeutics Announces Key Data at ASN Kidney Week 2024
- Marijuana Stocks Soar: Body and Mind and Global Compliance Lead Gains
- Legacy Housing Corporation Sets Earnings Call for Q3 2024
- Housing Initiatives: Upcoming Announcements You Should Know
- Shoals Technologies Group to Share Upcoming Earnings Insights
- Wins for Winnebago: New Leadership for Towable RV Success
- Market Watch: UnitedHealth Group Earnings Could Shape Trends
- Deutsche Bank Faces Shareholder Sell-Off Impacting Stock
- Analyzing Market Sentiment Surrounding Air Lease Company
- How $100 in Mastercard Became Over $2245 in 15 Years
- Phillips 66's Strategic Move: Selling Joint Venture Interest
- How An Investment in Arista Networks Can Multiply Wealth
- Coty Prepares for Strong FY25 with Adjusted EBITDA Growth
- Exploring Southern Company’s Short Interest Trends and Insights
- Understanding the Implications of Cirrus Logic's Short Interest
- Metallis Resources Secures $890,500 Funding for Exploration
- Exploring Unum's Dividend Potential for Investors Today
- LendingTree, Inc. Set to Announce Third Quarter Results Soon
- Transforming Senior Living: Aline Intelligence Revolutionizes Care